|
||||||||||||||||||||||||||
|
When India based biotechnology firm Biocon entered into an agreement with Pfizer recently, a lot of hype was generated on biosimilars being the next big cash cow for India. Biocon struck this deal to introduce biosimilar insulin products in India – the second diabetes capital in the world after China. Biosimilars[1] are generic impersonation of biotech Pre-requisites in meeting customer needs in rural markets There is no doubt that the banking industry in India has come a long way especially after embracing modern technology. However, Indian banks face unique challenges in terms of rural customers and financial inclusion in rural India. RBI had carried out researches on an all India |
|
|||||||||||||||||||||||||
|
Copyright © 2012 ValueNotes Database Pvt. Ltd.|All Rights Reserved|Terms of Use |
||||||||||||||||||||||||||
Recent Comments